Durvalumab – Cancer Drug Reimbursement, October 2026

Durvalumab (Imfinzi, AstraZeneca) has been approved for reimbursement in the Republic of Ireland through the Online Drug Management System (ODMS) in October 2026 for a new oncology indication.4 The approved indication is primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), in combination with carboplatin and paclitaxel (chemotherapy doublet). This reflects an […]

SMC Decisions – 12 October 2026

The Scottish Medicines Consortium (SMC) published advice on eight medicines following its meeting on 12 October 2026.3 Six medicines were accepted for use on the NHS in Scotland; two were not recommended. Accepted for use References – Scotland 3. October 2026 decisions news release. Scottish Medicines Consortium. October 2026. https://scottishmedicines.org.uk/about-us/latest-update/october-2026-decisions-news-release/

1 2 3 … 20

Add Your Heading Text Here

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.